Method for separating and determining calcipotriol and impurity J thereof based on HPLC method
Through high performance liquid chromatography and specific mobile phase combination, the impurity J in caspotriol was successfully isolated and detected, which solved the problem that the existing technology could not be effectively detected, and achieved efficient control of the quality of caspotriol products.
Patent Information
- Application Number
- CN202310658086.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-06-05
- Publication Date
- 2024-12-06
AI Technical Summary
The existing pharmacopoeia methods cannot effectively detect and separate impurity J in calpotriol, making it difficult to control the purity and quality of calpotriol.
Using high performance liquid chromatography, silica gel coated with starch-tris (3,5-xylylcarbamate) was used as the stationary phase of the chromatographic column, and the mobile phase was a mixed solution of anhydrous ethanol and n-hexane. Impurity J and calpotriol were separated by isometric elution, and qualitative identification and quantitative detection were performed using an ultraviolet detector.
It realizes effective separation and quantitative detection of caspotriol and impurity J, improves the quality control ability of the product, and the detection method is sensitive, simple, fast and accurate.
Smart Images

Figure CN119086793A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of analytical chemistry, and in particular relates to a method for separating and determining calcipotriol and its impurity J based on HPLC. Background Art
[0002] Calcipotriol is mainly used for topical treatment of psoriasis vulgaris. Calcipotriol exists in two forms: anhydrous and monohydrate. The chemical name of the anhydrous form is (5Z,7E,22E,24S)-24-cyclopropyl-9,10-openedocholesterol-5,7,10(19),22-tetraene-1α,3β,24-triol, and its molecular formula is C 27 H 40 O3, molecular weight is 412.60. The chemical name of the monohydrate is (5Z,7E,22E,24S)-24-cyclopropyl-9,10-openedocholesterol-5,7,10(19),22-tetraene-1α,3β,24-triol monohydrate, and its molecular formula is C 27 H 40 O3·H2O, molecular weight is 430.63. The structural formulas of the anhydrate and monohydrate of calcipotriol are shown in Formula I and Formula II respectively.
[0003] During the synthesis process of calcipotriol, a unique process impurity, impurity J, is generated, and the process clearance rate is poor. In the EP / USP / BP related substance analysis method, impurity J overlaps with calcipotriol, and the EP / USP / BP pharmacopoeia method cannot detect this impurity. The structural formula of impurity J is shown in Formula III.
[0004]
[0005] Therefore, in order to avoid the influence of impurity J on the purity and quality of the product, a new method needs to be established to separate and determine calcipotriol from impurity J in order to control the quality of calcipotriol.
[0006] In the prior art, the invention patent with publication number CN106908559B discloses a method for separating and determining a calcipotriol intermediate L and related impurities. The patent uses silica gel as the stationary phase and ethyl acetate-n-hexane as the mobile phase for separation and determination. The invention patent with publication number CN113533568B discloses a method for detecting procalcipotriol, impurity C and impurity D in calcipotriol ointment based on HPLC. The patent uses octadecylsilane bonded silica gel as the filler of the chromatographic column and uses water and acetonitrile as the mobile phase for detection. However, the above invention patents cannot achieve the qualitative and quantitative determination of impurity J in calcipotriol. Summary of the invention
[0007] In view of this, one of the objects of the present invention is to provide a method for simultaneously separating calcipotriol and impurity J based on high performance liquid chromatography, which achieves the effective separation of impurity J in calcipotriol and provides technical support for the qualitative and quantitative analysis of impurity J in calcipotriol in the later stage.
[0008] To achieve the above object, the present invention adopts the following technical solutions:
[0009] A method for simultaneously separating calcipotriol and impurity J based on high performance liquid chromatography, wherein the separated components are calcipotriol and impurity J; the structural formula of the impurity J is shown in formula III; the method comprises: using silica gel coated with starch-tris(3,5-xylylcarbamate) as a chromatographic column stationary phase, and the mobile phase is a mixed solution of anhydrous ethanol and n-hexane; the volume ratio of anhydrous ethanol to n-hexane in the mobile phase is 15-25:85-75; and sequentially separating impurity J and calcipotriol by isocratic elution;
[0010]
[0011] Furthermore, the calcipotriol is calcipotriol anhydrate and / or calcipotriol monohydrate; the structural formula of the calcipotriol anhydrate is shown in Formula I, and the calcipotriol monohydrate is shown in Formula II;
[0012]
[0013] Furthermore, the volume ratio of anhydrous ethanol to n-hexane in the mobile phase is 18-22:82-78.
[0014] More preferably, the volume ratio of anhydrous ethanol to n-hexane in the mobile phase is 20:80.
[0015] Preferably, the chromatographic column is CHIRALPAK AD-H, with specifications of 250 mm×4.6 mm and 5 μm.
[0016] Preferably, the column temperature is 20°C-30°C, preferably 25°C.
[0017] Preferably, the injection volume is 20 μl.
[0018] Furthermore, before separation, the test solution and the control solution are prepared with a diluent.
[0019] Preferably, the concentration of the test solution is 0.4 mg / ml, and the concentration of the control solution is 0.6 μg / ml.
[0020] Preferably, the diluent is a mobile phase, anhydrous ethanol or methanol.
[0021] More preferably, the diluent is a mixed solution of anhydrous ethanol and n-hexane, wherein the volume ratio of anhydrous ethanol to n-hexane is 20:80.
[0022] Furthermore, the flow rate of the mobile phase is 0.5 ml / min-1.5 ml / min, preferably 0.6 ml / min-1.0 ml / min, and more preferably 0.8 ml / min.
[0023] A second object of the present invention is to provide a method for qualitatively identifying calcipotriol and impurity J.
[0024] To achieve the above object, the present invention adopts the following technical solutions:
[0025] A method for qualitatively identifying calcipotriol and impurity J, comprising separating calcipotriol and impurity J by the method described in objective one, and detecting them by an ultraviolet detector after separation; the detection wavelength is 264±2nm.
[0026] Preferably, the detection wavelength is 264 nm.
[0027] Furthermore, the retention times from short to long are impurity J and calcipotriol.
[0028] Qualitative analysis can be performed based on retention time.
[0029] Furthermore, the volume ratio of anhydrous ethanol and n-hexane in the mobile phase is 20:80, the flow rate of the mobile phase is 0.8 ml / min, the chromatographic column is CHIRALPAK AD-H, its specifications are 250 mm×4.6 mm, 5 μm, the column temperature is 25°C; the detection wavelength is 264 nm; isocratic elution is performed according to the above conditions and a chromatogram is obtained.
[0030] When the retention time is 6.8±0.5min, it is determined to be the impurity J; when the retention time is 11.0±0.5min, it is determined to be the calcipotriol.
[0031] A third object of the present invention is to provide a method for quantitatively detecting calcipotriol and impurity J.
[0032] To achieve the above object, the present invention adopts the following technical solutions:
[0033] The method for quantitatively detecting calcipotriol and impurity J comprises the following steps:
[0034] (1) separation: separation of calcipotriol and impurity J by the method according to any one of claims 1 to 4;
[0035] (2) Detection: Detecting calcipotriol and impurity J using the method described in any one of claims 5 to 8;
[0036] (3) Content determination: Based on the chromatogram obtained in step (2), the contents of calcipotriol and impurity J were calculated by the main component self-reference method.
[0037] Further, the impurity J is within the concentration range of 0.1893 μg / ml to 3.7860 μg / ml, Y=1.1231X-0.0526, R=0.9996; and / or the calcipotriol is within the concentration range of 0.2003 μg / ml to 4.0055 μg / ml, Y=1.1681X-0.0729, r=0.9997; wherein Y is the Y axis, representing the peak area; X is the X axis, representing the concentration, and R represents the correlation coefficient. According to the linear slope, the correction factor of the impurity J is calculated to be within the range of 0.9 to 1.1, and can be calculated as 1.0 for the quantitative calculation of the impurity.
[0038] Further, the content of impurity J in calcipotriol is calculated using the principal component self-reference method according to the peak area detected by the detector, specifically comprising the following steps:
[0039] 1. Prepare the test solution: accurately measure the test sample and dissolve it in the diluent to obtain a test solution with a concentration of 0.4 mg / ml;
[0040] 2. Prepare the control solution: accurately measure an appropriate amount of the test solution and dilute it with a diluent to make a control solution with a concentration of 0.6 μg / ml;
[0041] 3. Take the test solution prepared in step 1 and the control solution prepared in step 2 for injection, perform high performance liquid chromatography analysis, record the chromatogram, and calculate the content of impurity J in calcipotriol according to the main component self-reference method.
[0042] Furthermore, a standard substance is prepared to obtain a chromatogram of a standard sample; and the peak area of the chromatogram obtained from the test sample is calculated according to the principal component self-comparison method.
[0043] The content of the components of the standard is known, while the content of the components of the test sample is unknown.
[0044] The obtained standard sample chromatogram can be stored in the database as a chromatographic material for quality control in the smart pharmaceutical factory, to help the robot determine whether the products it produces are qualified and to provide quantitative improvement analysis suggestions for unqualified products.
[0045] The beneficial effects of the present invention are:
[0046] 1. The present invention utilizes high performance liquid chromatography to separate and determine calcipotriol and its impurity J, thereby achieving effective control of impurities, fundamentally determining product quality, and having the advantages of being exclusive, sensitive, simple, rapid, and highly accurate. The present invention provides technical support for the quality control of calcipotriol and the quality improvement of preparation products.
[0047] 2. The detection method of the present invention can achieve the determination of calcipotriol and its impurity J within 30 minutes. The quantitative limit concentration of calcipotriol is 0.1905 μg / ml, the quantitative limit concentration of impurity J is 0.1913 μg / ml, the detection limit concentration of calcipotriol is 0.07620 μg / ml, and the detection limit concentration of impurity J is 0.07650 μg / ml. The detection method has high sensitivity, strong practicality, and accurate and reliable detection results, which is of great significance for achieving quality control of calcipotriol. BRIEF DESCRIPTION OF THE DRAWINGS
[0048] Figure 1 is the HPLC chart of the diluent (blank solution);
[0049] Figure 2 HPLC chart of system suitability solution;
[0050] Figure 3 is the HPLC chart of the control solution;
[0051] Figure 4 It is the HPLC chart of the test solution;
[0052] Figure 5 is the HPLC chart of the mixed solution;
[0053] Figure 6 HPLC graph of the quantitative limit solution;
[0054] Figure 7 HPLC graph of the detection limit solution;
[0055] Figure 8 It is the HPLC chart of the reference solution in precision;
[0056] Fig. 9 It is the HPLC chart of the test solution in accuracy;
[0057] Fig.10 It is the HPLC chart of the reference solution in accuracy;
[0058] Fig.11 HPLC chart of the control solution in accuracy;
[0059] Fig.12 This is the HPLC graph of the solution spiked with 80% in the accuracy test;
[0060] Fig.13 This is the HPLC graph of the solution spiked with 100% in accuracy;
[0061] Fig.14 This is the HPLC chart of the solution spiked with 120% in accuracy;
[0062] Fig.15The HPLC chart of the mixed solution is durability-flow rate 0.6 ml / min;
[0063] Fig.16 The HPLC chart of the mixed solution is durability-flow rate 1.0 ml / min;
[0064] Fig.17 The HPLC chart of the mobile phase mixed solution of n-hexane and anhydrous ethanol (78:22) is shown;
[0065] Fig.18 The HPLC chart of the mobile phase mixed solution of n-hexane and anhydrous ethanol (82:18) is shown;
[0066] Fig.19 Durability - HPLC chart of mixed solution at column temperature 20°C;
[0067] Fig. 20 The HPLC chart of the mixed solution is shown in Figure 1. DETAILED DESCRIPTION
[0068] The technical solution of the present invention will be further described clearly and completely in conjunction with specific embodiments below. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all the embodiments. Therefore, based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative work belong to the protection scope of the present invention.
[0069] In the embodiment of the present invention, the diluent is a mixed solution of anhydrous ethanol and n-hexane, wherein the volume ratio of anhydrous ethanol to n-hexane is 20:80.
[0070] In the examples of the present invention, the reference substance is derived from Chongqing Huabang Pharmaceutical Co., Ltd. or Chongqing Huabang Shengkai Pharmaceutical Co., Ltd.
[0071] In the embodiment of the present invention, the solution is prepared as follows:
[0072] System suitability solution: Take an appropriate amount of calcipotriol system suitability reference substance 1 (each 0.4 mg contains approximately 1.2 μg of impurity J and 0.4 mg of calcipotriol), dissolve it in a diluent and dilute it to make a solution containing approximately 0.4 mg per 1 ml.
[0073] Test solution: Take an appropriate amount of the product, weigh accurately, add diluent to dissolve and quantitatively dilute to make a solution containing about 0.4 mg per 1 ml.
[0074] Control solution: Accurately measure an appropriate amount of the test sample solution and dilute it with a diluent to make a solution containing approximately 0.6 μg per 1 ml.
[0075] In the embodiment of the present invention, the impurity J content is calculated as follows:
[0076]
[0077] Where: Ar is the peak area of impurity J in the chromatogram of the test solution;
[0078] A S —The peak area of the main peak in the chromatogram of the control solution.
[0079] In the embodiment of the present invention, impurity A is (5Z,7E,22E)-24-cyclopropyl-1α,3β-dihydroxy-9,10-opened cholesteryl-5,7,10(19),22-tetraen-24-one, and its chemical formula is 27 H 38 O3, molecular weight 410.60, structural formula as shown in formula IV; impurity B is (5Z,7Z,22E,24S)-24-cyclopropyl-9,10-opened cholesteryl-5,7,10(19),22-tetraene-1α,3β,24-triol, chemical formula C 27 H 40 O3, molecular weight 412.61, structural formula as shown in formula V; impurity C is (5E,7E,22E,24S)-24-cyclopropyl-9,10-opened cholesteryl-5,7,10(19),22-tetraene-1α,3β,24-triol, chemical formula C 27 H 40 O3, molecular weight 412.61, structural formula as shown in formula VI; impurity D is (5Z,7E,22E,24R)-24-cyclopropyl-9,10-opened cholesteryl-5,7,10(19),22-tetraene-1α,3β,24-triol, chemical formula C 27 H 40 O3, molecular weight 412.61, structural formula as shown in formula VII; impurity E is racemic-(5Z,7E,24S)-24-cyclopropyl-9,10-opened cholesteryl-5,7,10(19)-triene-1α,3β,24-triol, chemical formula C 27 H 42 O3, molecular weight 414.63, structural formula as shown in formula VIII; impurity F is (5Z,7E,22E,24S)-24-cyclopropyl-1α,3β-di(tert-butyldimethylsilyloxy)-9,10-opened cholesteryl-5,7,10(19),22-tetraen-24-ol, chemical formula C 39 H 68O3Si2, molecular weight is 641.13, the structural formula is shown in formula IX; impurity I is (6S,7R,8R,22E,24S)-24-cyclopropyl-6,8:7,19-bicyclo-9,10-opened cholesteryl-5(10),22-diene-1α,3β,24-triol, molecular formula is C 27 H 40 O3, molecular weight is 412.61, and the structural formula is shown in Formula X.
[0080]
[0081] Example 1
[0082] The instrument and chromatographic conditions used in this example are as follows:
[0083] The high performance liquid chromatograph was SHIMADZU LC-20AT; the chromatographic column was CHIRALPAK AD-H, 250 mm × 4.6 mm, 5 μm; the mobile phase was a mixed solution of anhydrous ethanol and n-hexane, wherein the volume ratio of anhydrous ethanol to n-hexane was 20:80; the wavelength was 264 nm; the column temperature was 25 °C; the flow rate was 0.8 ml / min; and the injection volume was 20 μl.
[0084] Take the diluent, system suitability solution, test solution and control solution respectively, perform HPLC analysis according to the above chromatographic conditions, record the chromatogram, and the results are as follows: Figure 1-Figure 4 As shown, Figure 2-Figure 4 The corresponding integration results are shown in Tables 1 to 3. It can be seen from the results that the diluent does not interfere with the detection of the sample. In the system suitability solution chromatogram, the peak order is impurity J and calcipotriol, which can be effectively separated with a separation degree greater than 1.5; calculated by the main component self-control method, the content of impurity J in the test solution is 0.03%.
[0085] Table 1. Figure 2 The integral results table
[0086]
[0087] Table 2. Figure 3 The integral results table
[0088]
[0089] Table 3. Figure 4 The integral results table
[0090]
[0091] Example 2. Selection of Chromatographic System and Chromatographic Column
[0092] This example investigates the chromatographic system and chromatographic column, and the results are shown in Table 4. As can be seen from Table 4, by adjusting the mobile phase ratio, in the reverse system, there is no separation effect between impurity J and the main peak. Therefore, it is considered to use a normal phase system to detect impurity J, and CHIRALCEL IC column and CHIRALCEL AD-H column are used for method screening and optimization, and finally the normal phase system is determined. The chromatographic column uses CHIRALCEL AD-H column (4.6×250mm, 5μm) to separate impurity J and calcipotriol well.
[0093] Table 4. Results of the selection of chromatographic system and chromatographic column
[0094]
[0095]
[0096] Example 3. Selection of mobile phase
[0097] This example further examines the mobile phase. A CHIRALCEL AD-H column (4.6×250 mm, 5 μm) was used, and n-hexane-isopropanol and n-hexane-anhydrous ethanol were used as the mobile phases to separate impurity J and calcipotriol. The screening process is shown in Table 5. After screening, the present invention selected n-hexane-anhydrous ethanol (80:20) as the mobile phase, and all impurities (including impurities B, C, D, E) and impurity J detected in the EP / BP related substances (reverse HPLC) system were prepared into a mixed solution and injected under the chromatographic conditions. The measurement results are shown in Table 5.
[0098] Table 5. Mobile phase selection
[0099]
[0100] Example 4. Specificity experiment
[0101] This study verified the specificity of the detection scheme of Example 1, including a blank solvent interference experiment, and verified the separation of possible impurities (impurity A, impurity C, impurity D, impurity E, impurity F, and impurity I may also be present in calcipotriol) by the chromatographic system: an appropriate amount of each impurity was weighed, diluted with a diluent to make a 4 μg / ml solution as a single needle positioning solution, and a mixed solution containing calcipotriol, impurity J and the above impurities was prepared (each 1 ml contained approximately 0.4 mg of calcipotriol and approximately 4 μg of each impurity), and the samples were injected separately.
[0102] Results: Blank solvent spectrum is as follows: Figure 1 As shown, the mixed solution spectrum is as Figure 5 As shown, the specificity test results are shown in Table 6, which shows that the blank solvent (V 无水乙醇 -V 正己烷=20:80) and the known impurities have no interference on the detection of impurity J. Impurity I does not produce a peak in this system; the maximum concentration of impurity C in the control solution (concentration: 0.6μg / ml) is 0.006μg / ml, (0.6μg / ml×1.0% (the control limit of impurity C in the test sample shall not exceed 1.0%)), which is much lower than the detection limit of the main component of this system (0.07620μg / ml), and can be ignored. Impurity C has no interference on the control solution. The separation degree between impurity J and the adjacent peak is 1.44, which is greater than 1.2. The results show that other impurities have good separation from the main component and impurity J, and the method of the present invention has good specificity.
[0103] Table 6. Specificity results table
[0104]
[0105] Example 5. Sensitivity experiment
[0106] Weigh appropriate amounts of impurity J and calcipotriol, respectively, add diluent to dissolve and dilute to prepare a solution containing 0.1905 μg of calcipotriol and 0.1913 μg of impurity J per 1 ml as the quantitative limit solution; add diluent to dilute to prepare a solution containing 0.07620 μg of calcipotriol and 0.07650 μg of impurity J per 1 ml as the detection limit solution, and inject them separately.
[0107] Results: The quantitative limit spectra and detection limit spectra are as follows: Figure 6 and Figure 7 The integration results are shown in Table 7 and Table 8, respectively. The quantification limit of calcipotriol is 0.1905μg / ml, and the quantification limit of impurity J is 0.1913μg / ml, which is expressed as 0.05% in the finished product, S / N is ≥10:1, and the peak area RSD is less than 10.0%. The detection limit of calcipotriol is 0.07620μg / ml, and the detection limit of impurity J is 0.07650μg / ml, which is expressed as 0.02% in the finished product, and S / N is ≥3:1. This shows that this method has high sensitivity.
[0108] Table 7. Figure 6 The integral results table
[0109]
[0110] Table 8. Figure 7 The integral results table
[0111]
[0112] Example 6. Linearity and correction factors
[0113] Weigh appropriate amounts of impurity J and calcipotriol, and prepare a series of linear solutions containing both calcipotriol and impurity J by stepwise dilution. The concentration range of these solutions is from the method quantitative limit to 1.0% of the test solution concentration, specifically 0.05%, 0.08%, 0.1%, 0.15%, 0.2%, 0.3%, 0.5%, 1.0% of the test solution concentration. Each 1 ml of dilution contains calcipotriol and impurity J, and its concentration gradient is used to establish a standard curve to evaluate the linear range and quantitative lower limit of the method. Samples are injected in order from low to high concentration, and the chromatogram is recorded. The concentration X (μg / ml) is linearly regressed against the peak area Y by the least squares method to calculate the regression equation and correlation coefficient.
[0114] Results: The regression equation of impurity J is Y=1.1231X-0.0526, and the correlation coefficient R is 0.9996, indicating that the impurity J has a good linear relationship in the concentration range of 0.1893μg / ml~3.7860μg / ml (LOQ~1.0%); the regression equation of calcipotriol is Y=1.1681X-0.0729, and the correlation coefficient R is 0.9997, indicating that the calcipotriol has a good linear relationship in the concentration range of 0.2003μg / ml~4.0055μg / ml (LOQ~1.0%).
[0115] According to the linear slope, the correction factor of impurity J is calculated to be in the range of 0.9 to 1.1, and can be taken as 1.0 for quantitative calculation of impurities. Therefore, the quantitative method of impurity J in calcipotriol is selected as "calculation by principal component self-reference method".
[0116] Example 7. Precision
[0117] Test solution: Take about 4 mg of calcipotriol monohydrate, weigh accurately, place in a 10 ml volumetric bottle, add diluent to dissolve and dilute to scale, shake well, and the solution is ready. (Prepare 6 portions in parallel)
[0118] Control solution: Accurately measure 1.0 ml of the test solution, place it in a 100 ml volumetric flask, add diluent to dilute to the scale, shake well, then accurately measure 1.5 ml, place it in a 10 ml volumetric flask, add diluent to dilute to the scale, shake well, and obtain.
[0119] Take 20 μl of the test solution and the control solution for injection, record the chromatogram, and calculate the content and RSD of impurity J in 6 test solutions according to the principal component self-reference method.
[0120] In order to investigate the influence of random variation factors on precision, different analysts conducted the test at different times. Six test solutions and reference solutions were prepared in parallel by the same method, and the chromatograms were recorded. The content and RSD of impurity J in the six test solutions were calculated by the principal component self-reference method, and the RSD of the impurity J content values in a total of 12 test solutions detected by different analysts was calculated.
[0121] Results: Figure 4 and Figure 8 As shown, Figure 8 The integration results are shown in Table 9. The average values of the impurity J detected in 6 test solutions of different personnel are about 0.03%, and the RSDs are 5.2% and 2.7% respectively. The RSD of the impurity J content detected in 12 samples of two people is 4.8%, which is less than 10.0%. This shows that the technical solution has good precision.
[0122] Table 9. Figure 8 The integral results table
[0123]
[0124] Example 8. Accuracy
[0125] 1. Solution preparation:
[0126] Reference substance stock solution: Accurately weigh 4.010 mg of impurity J, place in a 10 ml volumetric flask, add diluent to dissolve and dilute to the scale, shake well, accurately measure 0.5 ml, place in a 50 ml volumetric flask, add diluent to dilute to the scale, shake well, and obtain.
[0127] Reference substance solution: Accurately measure 1.5 ml of reference substance stock solution, place in a 10 ml volumetric flask, add diluent to dilute to the scale, shake well, and obtain.
[0128] Test sample stock solution: Accurately weigh 49.96 mg of calcipotriol monohydrate, place in a 25 ml volumetric flask, add diluent to dissolve and dilute to the scale, shake well, and obtain.
[0129] Test sample solution (unspecified solution): Accurately measure 2.0 ml of the test sample stock solution, place it in a 10 ml volumetric flask, add diluent to dilute to the scale, shake well, and obtain.
[0130] Control solution: Accurately measure 1 ml of the test solution, place it in a 100 ml volumetric flask, add diluent to dilute to the scale, shake well, accurately measure 1.5 ml, place it in a 10 ml volumetric flask, add diluent to dilute to the scale, shake well, and obtain.
[0131] Spiked sample solution: accurately measure 2.0ml of the test sample stock solution and place it in 9 10ml volumetric bottles respectively, then accurately measure 1.2ml, 1.2ml, 1.2ml, 1.5ml, 1.5ml, 1.8ml, 1.8ml, 1.8ml of the reference sample stock solution and place it in the above 10ml volumetric bottles respectively, add diluent to dilute to the scale, shake well, and you will get 80% spiked sample solution, 100% spiked sample solution, and 120% spiked sample solution. (3 copies for each concentration)
[0132] 2. Determination method: Take the test solution, reference solution, control solution and each spiked sample solution and inject them respectively, record the chromatograms, and calculate the recovery rate of impurity J according to the impurity reference external standard method and the main component self-reference method with correction factor.
[0133] Results: Figures 9 to 14 As shown, the integration results are shown in Table 10. The average recovery rate of impurity J calculated by the external standard method of impurity reference substance is 100.5%, and the RSD is 1.6%; the average recovery rate of impurity J calculated by the main component self-reference method with correction factor is 103.3%, and the RSD is 1.6%. The recovery rates are all within the range of 90% to 108%, indicating that the technical solution is accurate and good.
[0134] Table 10. Figure 9-14 The integral result table
[0135]
[0136]
[0137] Example 7. Durability
[0138] Calcipotriol, impurity J and each impurity detected in the reverse HPLC system (impurity B, C, D, E) were added with diluent to prepare a mixed solution for injection, and the mobile phase ratio, column flow rate and column temperature were adjusted respectively. After the instrument system was stable, the tests were performed separately and the separation between each peak was recorded.
[0139] Results: Figures 15 to 20 As shown in Table 11, when the column flow rates are 0.6 and 1.0, the minimum separations of impurity J and calcipotriol from the adjacent peaks are 2.36 and 2.16, respectively; when the mobile phase ratios of n-hexane-anhydrous ethanol are 78:22 and 82:18, respectively, the minimum separations of impurity J and calcipotriol from the adjacent peaks are 2.01 and 2.42, respectively; when the column temperatures are 20°C and 30°C, the minimum separations of impurity J and calcipotriol from the adjacent peaks are 1.85 and 1.99, respectively.
[0140] When the column flow rate, mobile phase ratio and column temperature fluctuated greatly, the separation between impurity J and adjacent impurity peaks was greater than 1.2, indicating that this method has good durability.
[0141] Table 11. Durability results
[0142]
Claims
1. A method for simultaneously separating calcipotriol and impurity J based on high performance liquid chromatography, characterized in that: The separated components are calcipotriol and impurity J; the structural formula of the impurity J is shown in formula III; the method is: using silica gel coated with starch-tris (3,5-xylylcarbamate) as the chromatographic column stationary phase, and the mobile phase is a mixed solution of anhydrous ethanol and n-hexane; the volume ratio of anhydrous ethanol to n-hexane in the mobile phase is 15-25:85-75; impurity J and calcipotriol are separated in sequence by isocratic elution; 2. The method according to claim 1, characterized in that The calcipotriol is calcipotriol anhydrate and / or calcipotriol monohydrate; the structural formula of the calcipotriol anhydrate is shown in Formula I, and the calcipotriol monohydrate is shown in Formula II; 3. The method according to claim 1, characterized in that The volume ratio of anhydrous ethanol to normal hexane in the mobile phase is 18-22:82-78.
4. The method according to claim 1, characterized in that: The flow rate of the mobile phase is 0.5 ml / min-1.5 ml / min.
5. A method for qualitatively identifying calcipotriol and impurity J, characterized in that: The method according to any one of claims 1 to 4 is used to separate calcipotriol and impurity J, and after separation, an ultraviolet detector is used for detection; the detection wavelength is 264±2nm.
6. The method according to claim 5, characterized in that The retention times from shortest to longest are impurity J and calcipotriol.
7. The method according to claim 5, characterized in that The volume ratio of anhydrous ethanol to n-hexane in the mobile phase is 20:80, the flow rate of the mobile phase is 0.8 ml / min, the chromatographic column is CHIRALPAK AD-H, the specification of which is 250 mm×4.6 mm, 5 μm, the column temperature is 25°C; the detection wavelength is 264 nm; isocratic elution is performed according to the above conditions and a chromatogram is obtained.
8. The method according to claim 7, characterized in that When the retention time is 6.8±0.5min, it is determined to be the impurity J; when the retention time is 11.0±0.5min, it is determined to be the calcipotriol.
9. A method for quantitatively detecting calcipotriol and impurity J, characterized in that: The following steps are involved: (1) separation: separation of calcipotriol and impurity J by the method according to any one of claims 1 to 4; (2) Detection: Detecting calcipotriol and impurity J using the method described in any one of claims 5 to 8; (3) Content determination: Based on the chromatogram obtained in step (2), the contents of calcipotriol and impurity J were calculated by the main component self-reference method.
10. The method according to claim 9, characterized in that The impurity J is in the concentration range of 0.1893 μg / ml to 3.7860 μg / ml, Y=1.1231X-0.0526, R=0.9996; and / or the calcipotriol is in the concentration range of 0.2003 μg / ml to 4.0055 μg / ml, Y=1.1681X-0.0729, r=0.9997; wherein Y is the Y-axis, representing the peak area; X is the X-axis, representing the concentration, and R represents the correlation coefficient.
